New Laser Defies Conventional Wave Physics – ENGINEERING.com

Schematic of the BIC laser. (Image courtesy of Kant Group/UC San Diego.)

BICs defy the norm of conventional waves, which escape in an open system. In contrast, BICs remain localized or confined despite the open pathways.

The laser has a thin semiconductor membranemade of gallium, phosphorous, arsenic and indiumconstructed as an arrangement of nano-sized cylinders. The membrane is suspended in air and a network of supporting bridges interconnect with its cylinders, providing stability.

With such unique properties, BIC lasers can be adjusted to emit light beams of various wavelengths. This can prove useful in the medical field when precisely targeting cancer cells.

The BIC system was able to emit a low frequency laser beam of its own when researchers used a high frequency laser beam to power the membrane. The lower frequency beam was consistent with telecommunication frequency.

BICs can also enable more powerful optical communication systems and computerscarrying up to 10 times more information compared to current methodsby emitting specific vector beams.

The size of the system can also be scaled up to produce high power lasers for defense and industrial applications. Boubacar Kant, electrical engineering professor, UC San Diego Jacobs School of Engineering, who led the research said, A fundamental challenge in high power lasers is heating and with the predicted efficiencies of our BIC lasers, a new era of laser technologies may become possible.

Right now, this is a proof of concept demonstration that we can indeed achieve lasting action with BICs, said Kant, ...And whats remarkable is that we can get surface lasing to occur with arrays as small as 8 x 8 particles.

The popular VCSELs (vertical-cavity surface-emitting lasers) used in high-precision sensing and data communications require much more power and need about 100 times larger arrays than the potential BICSEL (bound state in the continuum surface-emitting laser). With hopes of replacing VCSELs with BICELs someday, the team has filed a patent. This new type of light source could accompany smaller devices that will require less power.

The next step for Kants team is to create electrically powered BIC lasers, rather than their current optically powered system . "An electrically pumped laser is easily portable outside the lab and can run off a conventional battery source," Kant said.

For more information, visit their published work in the journal Nature.

See the rest here:

New Laser Defies Conventional Wave Physics - ENGINEERING.com

Overcoming hurdles in CRISPR gene editing to improve treatment – Phys.Org

February 7, 2017 A cartoon shows gene editing through engineered CRISPR/Cas9En delivery in the Rotello lab at UMass Amherst. The researchers have overcome an obstacle in the technology by designing a delivery system using nanoparticles to assist CRISPR/Cas9 across the cell membrane and into the nucleus while avoiding entrapment by cellular machinery. Credit: UMass Amherst

More and more scientists are using the powerful new gene-editing tool known as CRISPR/Cas9, a technology isolated from bacteria, that holds promise for new treatment of such genetic diseases as cystic fibrosis, muscular dystrophy and hemophilia. But to work well, the new gene-clipping tool must be delivered safely across the cell membrane and into its nucleus, a difficult process that can trigger the cell's defenses and "trap" CRISPR/Cas9, greatly reducing its treatment potential.

Now, researchers in nanochemistry expert Vincent Rotello's laboratory at the University of Massachusetts Amherst have designed a delivery system using nanoparticles to assist CRISPR/Cas9 across the membrane and into the cell nucleus while avoiding entrapment by cellular machinery. Details appear in a recent issue of the journal ACS Nano.

The lab's experiment leader, Rubul Mout, says, "CRISPR has two components: a scissor-like protein called Cas9, and an RNA molecule called sgRNA that guides Cas9 to its target gene. Once the Cas9-sgRNA pair gets to the destination gene in the nucleus, it can interrogate its genetic mistakes and correct them with the help of the host cell's repair machinery."

He points out that since CRISPR's potential was first discovered in 2012, gene editing or genome engineering has quickly become an intense research topic in biology and medicine. The goal is to treat otherwise incurable genetic diseases by manipulating diseased genes. "However, to achieve this, biotech and pharmaceutical companies are constantly searching for more efficient CRISPR delivery methods," he adds.

The new delivery method Rotello, Mout and colleagues designed involves engineering the Cas9 protein, named Cas9En, and carrier nanoparticles. Rotello says, "By finely tuning the interactions between engineered Cas9En protein and nanoparticles, we were able to construct these delivery vectors. The vectors carrying the Cas9 protein and sgRNA come into contact with the cell membrane, fuse, and release the Cas9:sgRNA directly into the cell cytoplasm."

"Cas9 protein also has a nuclear guiding sequence that ushers the complex into the destination nucleus. The key is to tweak the Cas9 protein," he adds. "We have delivered this Cas9 protein and sgRNA pair into the cell nucleus without getting it trapped on its way. We have watched the delivery process live in real time using sophisticated microscopy."

Mout and colleagues say they can now deliver the Cas9 protein and sgRNA pair into about 90 percent of cells grown in a culture dish with an editing efficiency of about 30 percent. "Ninety percent cytosolic/nuclear delivery is a huge improvement compared to others methods," Mout points out.

The researchers believe that the Cas9En may also serve as a platform for delivery of a variety of other materials such as polymers, lipid nanoparticles or self-assembling peptides. Rotello says, "Now that we have achieved efficient gene editing in cultured cells, we are aiming to edit genes in pre-clinical animal models. We are also interested in gene editing for adoptive therapies, where a diseased cell is isolated from a patient, corrected by CRISPR in the lab, and delivered back to the patient."

Apart from gene editing, the new delivery method may have other uses. For example, another important issue in biology and medicine is tracking DNA and RNA inside cells. Recently, CRISPR has been used to aid in this research. Moumita Ray, another researcher in the Rotello lab, says, "Our method allows the precise monitoring of Cas9 protein movement inside a cell, opening new opportunities in genomic research."

Explore further: Watching gene editing at work to develop precision therapies

More information: Rubul Mout et al. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing, ACS Nano (2017). DOI: 10.1021/acsnano.6b07600

University of Wisconsin-Madison engineers have developed methods to observe gene editing in action, and they're putting those capabilities to work to improve genetic engineering techniques.

A study in The Journal of Cell Biology by scientists at the University of Massachusetts Medical School reveals important new details about the inner workings of the CRISPR-Cas9 machinery in live cells that may have implications ...

The ability to control gene expression in cells allows scientists to understand gene function and manipulate cell fate. Recently, scientists have developed a revolutionary gene-editing tool, called CRIPSR/Cas9, which employs ...

Researchers have discovered a way to program cells to inhibit CRISPR-Cas9 activity. "Anti-CRISPR" proteins had previously been isolated from viruses that infect bacteria, but now University of Toronto and University of Massachusetts ...

(Phys.org)A team of researchers with members from several institutions in Japan has developed a new way to edit genes that involves cutting just one strand of DNA rather than both of them, as is normal for CRISPR-Cas9. ...

Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have for the first time created and used a nanoscale vehicle made of DNA to deliver a CRISPR-Cas9 gene-editing tool into ...

Inspired by the hair of blue tarantulas, researchers from The University of Akron lead a team that made a structural-colored material that shows consistent color from all viewing directions. This finding overturns the conventional ...

Using tiny snippets of DNA as "barcodes," researchers have developed a new technique for rapidly screening the ability of nanoparticles to selectively deliver therapeutic genes to specific organs of the body. The technique ...

How the natural defence force within our immune system attacks and destroys harmful invaders such as virus-infected and cancerous cells has been visualised in microscopic detail by scientists from UCL, Birkbeck, University ...

More and more scientists are using the powerful new gene-editing tool known as CRISPR/Cas9, a technology isolated from bacteria, that holds promise for new treatment of such genetic diseases as cystic fibrosis, muscular dystrophy ...

(Phys.org)In an effort to curb the adverse environmental impacts of paper production, researchers in a new study have developed a light-printable paperpaper that can be printed with UV light, erased by heating to 120 ...

Scientists used one of the world's most powerful electron microscopes to map the precise location and chemical type of 23,000 atoms in an extremely small particle made of iron and platinum.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View post:

Overcoming hurdles in CRISPR gene editing to improve treatment - Phys.Org

Flat lens opens a broad world of color – Harvard School of Engineering and Applied Sciences

Last summer, researchers at the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced a new, flat lens that could focus light with high efficiency within the visible spectrum. The lens used an ultrathin array of nanopillars to bend and focus light as it passed.

The announcement was hailed as a breakthrough in optics and was named among Science Magazines top discoveries of 2016.

But the lens had a limitation it could only focus one color at a time.

Now, the same team has developed the first flat lens that works within a continual bandwidth of colors, from blue to green. This bandwidth, close to that of an LED, paves the way for new applications in imaging, spectroscopy and sensing.

The research is published in Nano Letters.

One of the major challenges in developing a flat, broadband lens has been correcting for chromatic dispersion, the phenomenon where different wavelengths of light are focused at different distances from the lens.

Traditional lenses for microscopes and cameras including those in cell phones and laptops require multiple curved lenses to correct chromatic aberrations, which adds weight, thickness and complexity, said Federico Capasso, Robert L. Wallace Professor of Applied Physics and Vinton Hayes Senior Research Fellow in Electrical Engineering. Our new breakthrough flat metalens has built-in chromatic aberrations corrections so that a single lens is required.

Correcting for chromatic dispersion known as dispersion engineering is a crucial topic in optics, and an important design requirement in any optical systems that deals with light of different colors. The ability to control the chromatic dispersion of flat lenses broadens their applications and introduces new applications that have not yet been possible.

"By harnessing chromatic aspects, we can have even more control over the light, said Reza Khorasaninejad, a Research Associate in the Capasso Lab and first author of the paper. Here, we demonstrate achromatic flat lenses and also invent a new type of flat lens with reverse chromatic dispersion. We showed that one can break away from the constraints of conventional optics, offering new opportunities only bound by the designers imagination."

To design an achromatic lens a lens without chromatic dispersion the team optimized the shape, width, distance, and height of the nanopillars that make up the heart of the metalens. As in previous research, the researchers used abundant titanium dioxide to create the nanoscale array.

A scanning electron microscopeimage shows a side-viewof the metalens, withnanopillars optimized to focuscolors without chromatic dispersion.Scale bar: 200 nm. (Image courtesy of the Capasso Lab/Havard SEAS)

This structure allows the metalens to focus wavelengths from 490 nm to 550 nm, basically from blue to green, without any chromatic dispersion.

This method for dispersion engineering can be used to design various ultrathin components with a desired performance, said Zhujun Shi, a PhD student in the Capasso Lab and co-first author of the paper. This platform is based on single step lithography and is compatible with high throughput manufacturing technique such as nano-imprinting.

Harvards Office of Technology Development has filed patent applications on a portfolio of flat lens technologies and is working closely with Capasso and members of his research group to catalyze commercialization of this technology through a startup company.

The research publishedwas coauthored by Alexander Zhu, Wei Ting Chen, Vyshakh Sanjeev, and Aun Zaidi. It was supported in part by the Air Force Office of Scientific Research.This work was performed in part at Harvard Universitys Center for Nanoscale Systems (CNS), a member of the National Nanotechnology Coordinated Infrastructure (NNCI), which is supported by the National Science Foundation.

Read more here:

Flat lens opens a broad world of color - Harvard School of Engineering and Applied Sciences

Manufacturing Bits: Feb. 7 – SemiEngineering

The University of California at Santa Barbara claims to have developed the worlds smallest hammer.

The technology, dubbed the Hammer or microHammer, is geared for biomedical research. With funding from the National Science Foundation (NSF), the tiny hammer will allow researchers to get a cellular-level understanding when force is applied to brain cells. The project is part of the U.S.-based Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative. The initiative is aimed at revolutionizing the understanding of the human brain.

The nano-hammer, a cellular-scale machine, aims to solve a major problem. Mechanical forces are known to impact cells. But there is a lack of understanding in terms of the reactions of individual neural cells. This, in turn, could help researchers gain a better understanding of Alzheimers disease and other brain injuries.

The microHammer will allow researchers to get a cellular-level understanding of what happens when force is applied to neurons. (Source: UCSB)

Through a cell sorting technique, the Hammer is injected into a system. It flows through individual cells. Then, it subjects each of them to one of a variety of physical forces.

This in turn will elicit responses. This project will enable precision measurements of the physical, chemical and biological changes that occur when cells are subjected to mechanical loading, ranging from small perturbations to high-force, high-speed impacts, said Megan Valentine, an associate professor at UC Santa Barbara, on the universitys Web site. Our technology will provide significantly higher forces and faster impact cycles than have previously been possible, and by building these tools onto microfluidic devices, we can leverage a host of other on-chip diagnostics and imaging tools, and can collect the cells after testing for longer-term studies.

Our studies could transform our understanding of how cells process and respond to force-based signals, she said. These signals are essential in development and wound healing in healthy tissues, and are misregulated in diseases such as cancer.

Cell nanoscopy Traditional optical microscopy is used in life sciences. But the resolution is limited to half the wavelength of light or about 200nm, according to the Karlsruhe Institute of Technology (KIT).

So, the smallest cellular structures are sometimes blurred using traditional microscopy. Over the years, the industry has developed various techniques to overcome the problem, including the development of simulated emission depletion (STED) nanoscopy.

Now, KIT has refined the STED nanoscopy method. The new method, named STEDD or Stimulated Emission Double Depletion, modifies the image and suppresses the background noise. STEDD or STED2 is advantageous when analyzing three-dimensional sub-cellular structures.

A cancer cell under the microscope: The STED image (left) has lower resolution. In the STEDD image (right), the resolution is better. (Image: APH/KIT)

In fluorescence microscopy, a sample is scanned with a focused light beam. This makes dye molecules emit fluorescent light, according to KIT. The light is registered pixel-by-pixel to form an image.

In STED, a beam is overlapped by another beam. The light intensity is located around this beam. It produces a fine image, but the background has a lower resolution.

KIT has extended this STED method by adding another beam. The beam follows the STED beam with a time delay. It eliminates the signal in the center, causing the background excitation to remain. The STED method is based on recording two images, said Gerd Ulrich Nienhaus, a professor at KIT. Photons registered prior to and after the arrival of the STED2 beam contribute to the first and second image, respectively.

Resolving proteins The Institute for Research in Biomedicine (IRB Barcelona) has used various techniques to observe protein nanomachines or protein complexes in living cells at three dimensional images.

Researchers used a combination of super-resolution microscopy, cell engineering and computational modeling. This in turn allows them to observe protein complexes at 5nm resolutions. This is four times smaller than previous studies.

On the left, in vivo image of nanomachines using current microscopy; on the right, the new method allows 3D observation of nanomachines in vivo and provides 25-fold improvement in resolution. (O. Gallego, IRB Barcelona)

With the technology, it will be possible to study cellular proteins for applications such as health and disease. Being able to see protein complexes measuring 5nm is a great achievement, but there is still a long way to go to be able to observe the inside of the cell at the atomic scale that in vitro techniques would allow, said Oriol Gallego, an IRB Barcelona researcher.

Related Stories Manufacturing Research Bits: Jan. 31 Fiber-imprint patterning; measuring nanofibers. The Week In Review: Manufacturing (Feb. 3, 2017) Veeco buys Ultratech, Amkor buys Nanium; NIs instrument; DRAM shortage?

The rest is here:

Manufacturing Bits: Feb. 7 - SemiEngineering

Business Showcase : Sky and Space Global – Irish Tech News

By@SimonCocking

Describe the company the elevator pitch

Sky and Space Global will deploy nano-satellites constellation in orbit to provide affordable, global, narrow-band communication services to Anyone, Anywhere, Anytime.

How are you different?

Sky and Space Global is the first company to utilize nano-satellites in a constellation format in the communication domain. It is building a proprietary network management software platform that will enable the constellation to manage, monitor, and control itself in an automated fashion, which is a capability yet to be realized by a for-profit business model utilizing small-satellites in the communication domain. An inter-satellite connectivity-based constellation system focusing on the equatorial belt is an industry first and Sky and Space Global is doing it. The business is aiming to support existing and incoming telecom operators and service providers as they deliver affordable narrow-band services to remote locations that do not have access to reliable and affordable connectivity services. The company is also engaging fellow space industry participants in the small satellite industry and is well on its way in establishing its core principle of affordable connectivity being a basic human right.

When @PeterDiamandis founded @singularityu, he challenged the students to improve the lives of 1b people in 10 years. Were gonna do it in 4

Sky and Space Global (@SkySpaceGlobal) February 2, 2017

Why will the company / product do well?

There are almost 4 billion people living without mobile coverage, hence, a huge demand for connectivity services in remote locations. Mobile market is a crucial player in enabling companies to reach new customers and offer new services. The mobile industry is also a significant source of employment and job creation.

For the full potential of mobile to be realized, populations need access to mobile networks, and to affordable devices and services. Nano-satellites offer a great alternative to traditional satellite communications, which are very costly, and have the potential to provide affordable connectivity to anyone, anywhere, anytime in the world. The ability to provide mobile coverage in remote locations is vital for building a healthy information infrastructure in developing countries where poor connectivity is a barrier to education, business growth and economic prosperity.

Secure World Foundation recognizes SAS as one of the world leaders along with @OneWebOfficial @planetlabs and @SpireGlobal pic.twitter.com/JiWXONgGDl

Sky and Space Global (@SkySpaceGlobal) January 31, 2017

Where are you based?

As a global company, Sky and Space Global has centers in United Kingdom, Australia, Israel and Poland.

When was the company launched?

Incorporated on November 2015.

What have been your biggest wins to date?

Affordable #connectivity is a basic right, @Frost_Sullivan recognizes @SkySpaceGlobal for providing just that. https://t.co/z5ZUruoBCq

Frost & Sullivan BP (@FrostBPAwards) January 30, 2017

What type of people (market segment) are you trying to attract to your product?

Sky and Space Globals services will be supporting telecom operators and service providers to expand their existing networks and deliver low-cost narrow-band connectivity services to locations yet to realize reliable connectivity for basic voice and text services. In this way, Sky and Space Global will be supporting the existing communication layers while also establishing a value chain of its own moving forward.

Our business model is a B2B wholesale. Our existing customers are :

Our potential customers are :

Tell us about your team?

Our Team is composed of aerospace, satellite and software industry experts which their unique sector knowledge and long experience have enable Sky and Space Global to develop a company with highly potential to execute its vision and mission to bring Affordable communication to Anyone, Anywhere, Anytime.

On stage, Meir Moalem CEO of SAS and Barry Matsumori (@barrym) Senior VP Of Business Development And Advanced Concepts @virgingalactic pic.twitter.com/aSwK74Jwqz

Sky and Space Global (@SkySpaceGlobal) January 30, 2017

CEO Meir Moalem

A jet fighter pilot, Lt. Col (Res.) of the IAF, has over 20 years of experience in management, R&D and operation of state-of-the-art projects in Space Systems and UAS. Meir is a Founder of Sky and Space Global and its CEO and Managing Director.Meir served as the head of Space Systems Branch in the Israeli Air Force, led the MEDIEX experiment on Space Shuttle Columbia (STS-107) as the project manager for Israel first astronaut flight and led Israels satellite projects including Ofeq and Techsar. During his many years of service, Meir worked with high level national security contacts, planning for strategic security requirements, projects initiation, development and design management, policy making, total responsibility for planning, while managing multi-million project budgets.Meir holds a B.Sc. in Physics from Ben Gurion University, M.A. in national security from Tel Aviv University and is in final stage of his PhD. Meir was awarded the Israel National Security Award in 2009.

CTO Meidad Pariente

With more than 20 years of satellite and aerospace industry experience, Meidad is a founder of Sky and Space Global and its Chief Technical Officer.Meidad started as AMOS-1 satellite operator, later was the Deputy Mission Manager of AMOS-2, Chief systems engineer of AMOS-3 successfully launched in 2008, and special engineering advisor for AMOS-5, launched in 2011.Meidad was the chief systems engineer and led a team of Israeli engineers and scientists designing the VENUS project, an Israeli-French hyperspectral satellite.Meidad is a leading nanosatellite expert, having led projects in Israel, Europe and the USA. In 2014 Meidad and Maya led the Duchifat-1 project, the first Israeli nanosatellite which was launched successfully in June 2014 as part of a tertiary project. The Nano-satellite is still fully operational.Meidad holds a B.Sc in Physics from Tel Aviv University and a M.E. in Systems Engineering from the Technion Aerospace faculty.

COO Maya Glickman

With more than 14 years of hands-on experience, Maya Glickman is Sky and Space Globals satellite mission analyst, orbit designer, and satellite operating expert.Maya was a Senior Satellite Engineer of communications satellites with IsraelAerospace Industries. Maya was part of the AMOS-3 development team, LEOPand IOT missions as well as the AMOS-1 hand-over to Intelsat and led the end-of-life mission team.Maya designed and optimized several large scale constellations for earth observation and communication use, and was involved in the assembly, integration and testing of Duchifat-1, the first Israeli nanosatellite.Maya has a B.Sc. in Aerospace Engineering and M.Ein System Engineering, bothfrom theTechnion Aerospace faculty, and is also a graduate of the 2003 ISU summer session program in Adelaide, Australia.

What are you long term plans for your product / company?

Our 2020 (and beyond) vision, is to make a better world for billions of people off the communication grid, by providing Affordable voice, instant messaging and data transfer for Anyone, Anytime, Anywhere.

What tech gadgets do you wish you could use to help you?

Beam me up,Scotty

How do people get in touch with you?

Website http://www.skyandspace.global

Facebook Page http://www.facebook.com/skyandspaceglobal/

LinkedIn page http://www.linkedin.com/company-beta/10424893/

Twitter https://twitter.com/SkySpaceGlobal

Email contact@skyandspace.global

If you would like to have your company featured in the Irish Tech News Business Showcase, get in contact with us at Simon@IrishTechNews.net or on Twitter: @SimonCocking

AustraliaBusiness ShowcaseIsraelPolandSky and Space GlobalUnited KingdomVirgin Galactic

Visit link:

Business Showcase : Sky and Space Global - Irish Tech News

School of Medicine Building Opens at Nazarbayev University – Astana Times

ASTANA A new building opened Jan. 25 at Nazarbayev University School of Medicine.

Nursultan Nazarbayev meets with students. Photo credit: akorda.kz

Designed by leading American architectural firm Perkins + Will, the 39,825-square metre institute includes research and teaching laboratories, a simulation centre, anatomical laboratory, lecture halls, group study rooms, library and dining room.

Kazakh President Nursultan Nazarbayev met with faculty and students as part of the official opening.

The level of teaching and medical school equipment can be compared with the worlds top universities. I am expecting life-changing scientific discoveries from you. The research, laboratory capacity and scientific potential of teachers allow you to find new methods to treat the most difficult diseases and prolong life. This school is created as the main basic school which will lead the way for other universities, he said.

Photo credit: akorda.kz

The head of state noted the world is currently experiencing scientific progress in the fields of medicine and biology, subjects which play major roles in conjunction with information technology.

All subjects are interrelated and a lot of discoveries occur at their confluence. We should develop science and we need versatile scientists, he said.

The University of Pittsburgh will serve as the schools strategic academic partner.

We will cooperate as part of the Doctor of Medicine programme development. It is a four-year programme designed according to an American model. Students entering the programme must have a Bachelors degree. We will also cooperate with the School of Nursing to develop a programme for training nurses. We conducted a six-month course titled professional development programme for the nurses to work at the Universal Medical Centre clinics, which became part of our university in 2016. We plan to launch a two-year undergraduate programme for practicing nurses this year, School of Medicine Executive Director Nurlan Algashov told The Astana Times.

Photo credit: akorda.kz

The school has a diverse faculty, with local teachers and professors from the U.S., U.K., Italy, Singapore and Malaysia.

Our local teachers are mainly practitioners with knowledge of English. We pay special attention to teaching experience and research activities when we select teachers, he said.

Opened in 2015, the School of Medicine has a mission to train physicians to become highly qualified doctors with research skills and a fundamental understanding of medical science who are ready to contribute to the development of medicine and medical science in Kazakhstan.

The school has a current enrolment of 75 students for the Doctor of Medicine (MD) and Master of Public Health (MPH) programmes. A Masters course in molecular medicine is scheduled to launch in August.

The simulation centre enables students to learn and practice with mannequins and other medical simulators. The practice allows students the chance to master specific skills, then work with patients. The school is also teaching students using standardised patients, specially-trained individuals who pretend to be patients.

Students also have opportunity to participate in small research summer projects in collaboration with second year teachers and are required to participate in research projects with faculty members the next year.

Read the original post:

School of Medicine Building Opens at Nazarbayev University - Astana Times

A protein called PERK may be a target for treating progressive supranuclear palsy – Science Daily

A protein called PERK may be a target for treating progressive supranuclear palsy
Science Daily
Scientists at the German Center for Neurodegenerative Diseases (DZNE) and the Technical University of Munich (TUM) have now discovered a molecular mechanism that may help in the search for effective treatments. Their study focusses on a protein called ...

Read the original:

A protein called PERK may be a target for treating progressive supranuclear palsy - Science Daily

Diversity of Kids’ Cancer More Epigenetic Than Genetic – Genetic Engineering & Biotechnology News

Tumor cells may multiply quickly or slowly, and sow metastasis and dodge the immune system more or less strenuously. All this variability may be ascribed to genetic heterogeneitybut not always. Some cancers have low genetic complexity. For example, childhood cancers tend to harbor less genetic complexity than the cancers that afflict the elderly. And yet childhood cancers, like other cancers, manifest in diverse ways.

To what may the heterogeneity of childhood cancers be ascribed, if not genetic diversity? Epigenetic diversity, suggests a team of scientists based at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences.

The CeMM-led team recently completed a study of Ewing sarcoma, an aggressive bone cancer in children and adolescents. A single genetic defectthe EWS-ETS fusionis present in all tumors, initiating cancer development and defining Ewing sarcoma as a disease. But the tumors carry very few DNA mutations that could explain the observed differences in the disease course of Ewing sarcoma patients.

After profiling many Ewing tumors, the scientists found that the disease's clinical diversity is reflected by widespread epigenetic heterogeneity. The scientists presented their results January 30 in the journal Nature Medicine, in an article entitled DNA Methylation Heterogeneity Defines a Disease Spectrum in Ewing Sarcoma.

The article described how the scientists performed genome-scale DNA methylation sequencing for a large cohort of Ewing sarcoma tumors and analyzed epigenetic heterogeneity on three levelsbetween cancers, between tumors, and within tumors.

We observed consistent DNA hypomethylation at enhancers regulated by the disease-defining EWS-FLI1 fusion protein, thus establishing epigenomic enhancer reprogramming as a ubiquitous and characteristic feature of Ewing sarcoma, the authors of the Nature Medicine article wrote. DNA methylation differences between tumors identified a continuous disease spectrum underlying Ewing sarcoma, which reflected the strength of an EWS-FLI1 regulatory signature and a continuum between mesenchymal and stem cell signatures.

The scientists established that there is substantial epigenetic heterogeneity within Ewing sarcoma tumors, particularly in patients with metastatic disease. Moreover, the researchers found that Ewing sarcoma tumors appear to retain part of the characteristic DNA methylation patterns of their cell of origin.

The scientists suggest that the diverse clinical courses observed among Ewing sarcoma patients may be explained epigenetically: As DNA methylation influences gene activity, the combination of Ewing sarcoma specific and cell-of-origin specific patterns can lead to different outcomes. The epigenetic diversity also appears to correlate with the tumors' aggressiveness and metastatic state.

Regarding the future of Ewing sarcoma treatment, study co-director Heinrich Kovar, scientific director of St. Anna Children's Cancer Research Institute, optimistically stated: "These new insights into the biology of Ewing sarcoma provide the basis for developing epigenetic biomarkers that can reliably predict disease course and therapy response. After two decades of stagnation in the therapy for patients with Ewing sarcoma, we expect new impulses for personalized therapy of this aggressive cancer."

"Our findings in Ewing sarcoma also provide an interesting concept for other cancer with low genetic complexity," added Christoph Bock, principal investigator at CeMM and a co-director and corresponding author of the current study. "In the era of precision medicine, understanding the causes and consequences of tumor heterogeneity will be crucial to develop personalized therapies. Only with precise knowledge of the molecular mechanisms underlying each tumor can we hope to treat in a targeted way and with far fewer side effects."

Read more from the original source:

Diversity of Kids' Cancer More Epigenetic Than Genetic - Genetic Engineering & Biotechnology News

Oculus Studios Promises ‘Months Of High Profile Rollouts’, Here’s What’s Coming – UploadVR

Yesterday, Oculus announced the release date for what will be one of its first big Studios games this year, Rock Band VR. But theres plenty more where that came from.

Following the news, Jason Rubin, Head of Content at Oculus, tweeted out a tease that the launch of the Harmonix music game was Starting Months of high profile rollouts for the headset, suggesting were going to see many more Rift and Gear-exclusive games in the coming months.

Starting Months of high profile rollouts with #Rockband from @Harmonix for @Oculus Rift: https://t.co/W7offpnzzD

Jason Rubin (@Jason_Rubin) February 6, 2017

Thats a very exciting thought, but it left us wondering: What exactly is coming?

So we decided to round up all the Oculus Studios projects we know about right now and shine a spotlight on them below. Keep in mind we dont have release dates for any of these games yet so were not sure how far away from release they are.

What Is It?: Made to showcase the power of Touch, this is a gritty underground shooter where youll use inventive weapons to take down monstrous and robotic enemies, making use of cover and highly customizable guns.

Who Is Making It?: 4A Games, which is known for the Metro series of shooters. Theyre tonally very similar to Arktika, set in a bleak apocalyptic wasteland. This team knows a thing or two about making convincing environments.

Why Are We Excited?: 4A has plenty of experience in making moody, atmospheric shooters quite unlike anything weve seen in the VR industry so far. Arktika could prove to be a genuinely engaging VR FPS with a meaty campaign that takes us on an epic journey.

What Is It?: A first and third-person multiplayer warfare game, where you lead machines and soldiers into battle in a fight for what remains of the Earths resources. It is more top-down shooter than it is strategy game.

Who Is Making It?: Force Field VR, a new studio thats dedicated to the technology and is making several Studios projects. Were expecting big things from them going forward, not just in VR but in augmented reality too.

Why Are We Excited?: If you got into the recent beta that was available on the Oculus store then you should know. Landfall is proof that great gamepad-based gamesarent going anywherenow that Touch is here. The game is releasing later this month, so keep an eye out.

What Is It?: A Touch-starring sci-fi adventure in which you navigate around a space station using your hands. A routine repair job soon turns into a catastrophic incident, and players will be left fighting for survival in the cold depths of space.

Who Is Making It?: Ready at Dawn, which is known for its graphical prowess. Games like PS4s The Order: 1886 and the PSP God of War spin-offs pushed the hardware on which they were running to their limits, so were expecting them to do the same for Rift.

Why Are We Excited?: Lone Echo is easily the best-looking Rift game weve seen so far, but it includes some exciting gameplay mechanics too. Not only that, but theres a very promising multiplayer mode to go with the solo campaign. We have high hopes.

What Is It?: The automated future is here, and robots do a lot of jobs for us. Only this specific batch of droids has malfunctioned, and youre here to take them back in. One problem? They dont want to come with you, so theyll have to be returned piece by piece.

Who Is Making It?: Epic Games. You know, the guys behind Gears of War, Unreal Tournament, and the Unreal Engine that so many developers use to make their VR projects. We expect great things from such a high caliber developer.

Why Are We Excited?: Epic knows how to make AAA blockbusters better than anyone, and were expecting them to make one of VRs first. The best part is every Touch owner will be able to play it; Epic and Oculus are releasing the game for free.

What Is It?: A noir adventure game with a trippy horror twist. Wilsons Heart has you using Touch controllers to explore a seemingly abandoned mental asylum, where youll quickly find yourself questioning whats real and whats in your head.

Who Is Making It?: Twisted Pixel, a studio that made its name back in the days of Xbox Live Arcade with the Spolsion Man titles. They excel at making quirky, experimental projects and this looks to be no exception.

Why Are We Excited?: Wilsons Heart makes the best use of the Oculus Touch controllers weve seen in a game, and what weve played promises one of the most intriguing stories in VR so far. This is one of our most anticipated VR games in general, let alone from Studios.

Tagged with: oculus, Oculus Studios, robo recall, wilson's heart

Follow this link:

Oculus Studios Promises 'Months Of High Profile Rollouts', Here's What's Coming - UploadVR

Ebates joins slowly growing list of Edge extensions, only 22 so far – OnMSFT (blog)

With the Windows 10 AnniversaryUpdate, Microsoft introduced extensions to theEdge web browser. While weve already covered the variety of free extensions available for you to download, a recent report from Windows Central has pointed out thatEbates has joined the slowly growing list of Edge extensions.

With theEbates Cash Back extension, you can shop and save online with coupons and promo codes at over 2,000 stores all while earning Cash Back rewards. All you need to do to enjoy the benefits of this extension is to install it and shop online as you please. Then, when youre shopping, theEbates Button will remind you to activate Cash Back as you go from store to store. Its safe to say that thanks to the latest edition to the Edge extension family, you will save money, and have an extra piece of mind.

Unfortunately, while the Ebates extension now brings the total list to Edge extensions 22, it still lags far behind those of its closest competitor, Google Chrome. A visit to the Google Chrome Web Store shows an almost endless scrolling list of compatibleextensions from a variety of different fields and themes. But, on the bright side of things, Edge and Windows 10 market shares are increasing gradually, and Microsoft is working to make Edge even better in the Windows 10 Creators Update (better battery life anyone?)

Read more here:

Ebates joins slowly growing list of Edge extensions, only 22 so far - OnMSFT (blog)

Cloud computing key to precision medicine but security concerns persist – Healthcare IT News

Precision medicine promises to change the healthcare paradigm and create a powerful new model of care designed specifically for each individual, offering a much greater likelihood of effectiveness. But to realize much of this vision requires eliminating data silos and aggregating information from all sources Internet of Things, patient surveys, genomic data, EHRs and more into a central repository that gives clinicians worldwide access to this data.

Many believe the cloud will become the primary platform for data aggregation and harmonization. And thats the direction Nephi Walton, MD, informaticist and clinical geneticist at Washington University School of Medicine, is heading.

People are misled a bit by the benefits of cloud computing in this domain, Walton said. A lot of people are touting the advantage of data anywhere, which indeed is an advantage of cloud computing. But that is not the major role that the cloud will play in precision medicine. Its more related to the size of the data and the ability to analyze and access data quickly. And the ability to plug into cloud services of different types. There are certain things that lend themselves to cloud computing more than others, and in precision medicine it is more the large data sets involved.

A caregiver may have huge data sets, entire genomes, gigabytes on an individual. Historically, healthcare has placed all this data on huge servers; but when one has this large a data set on each patient, one really needs to use distributed computing, Walton explained.

Learn more at theCloud Computing ForumHIMSS17.Register here. University of Mississippi Medical Center finds big analytics gains in the cloud Intermountain exec: Cloud changes breadth and depth of innovation

When you think about who is doing it and allowing huge sets of analysis, you think of someone like Google; it is using database cloud computing technology, he explained. The advantage is setting up all of these large data sets in something similar to Google Big Table a database structure different from standard relational databases as it allows one to use a distributed model that enables rapid access to large amounts of data. Here you can quickly access lots of information and process it quickly.

That is where the power will be in terms of cloud computing and precision medicine, he added.

You will have someones genomic data in an accessible database where you can access all the people with certain conditions to do real-time analysis and apply new knowledge to large data sets quickly, he said.

Walton will be speaking on the benefits and challenges of using cloud computing with precision medicine at the HIMSS and Healthcare IT News Cloud Computing Forum in Orlando, Florida, on February 19, during the 2017 HIMSS Conference & Exhibition. Waltons session is entitled Precision Medicine and the Cloud.

One of the big challenges with cloud computing and precision medicine is peoples fear of data security, Walton said.

The thing people do not realize is that the cloud is probably in some ways more secure than what a lot of people are doing now, he said. I know of some organizations that are fearful of the security of putting the data out there in the cloud but that actually have serious gaping security holes that expose them to far more risk than would happen with cloud computing. Anytime you allow remote access to data your weakest link in security is your employees passwords. If you have any reasonable security, the weakest spot will be at the employee level.

Walton said most companies that provide cloud computing services have excellent reliability and security and can provide these things on a scale that would be difficult for smaller organizations and even challenging for larger organizations.

The issue is it is not cheap, he added. But when you look at all the people you employ for security and backup and maintenance and so forth, for smaller organizations it makes sense to turn to the cloud; for larger organizations, it depends.

In the end, healthcare organizations must understand why they wish to get into cloud computing before they actually do so, Walton advised.

Understand if you are doing it for the right reasons, that you have done a good analysis of not just the real obvious things and are not just jumping into the ring without fully understanding why, he said. If you do it from the perspective of you do not want to be the person who manages servers and worry about backups and data security, essentially what you are doing is putting off a lot of your IT expenses to someone else. You can build a cloud in-house. The question is can you do it more efficiently than someone who's job and mission it is to do that. You have to make sure you know why you are doing it and the benefits you will get from it.

HIMSS17runs from Feb. 19-23, 2017 at the Orange County Convention Center.

This article is part of our ongoing coverage of HIMSS17. VisitDestination HIMSS17for previews, reporting live from the show floor and after the conference.

Like Healthcare IT News onFacebookandLinkedIn

Go here to see the original:

Cloud computing key to precision medicine but security concerns persist - Healthcare IT News

Trump’s H-1B Visa Crackdown Threatens Cutting-Edge US Medicine – Bloomberg

From tiny startups to global giants, the companies that sustain the $324 billion U.S. biotech industry are increasingly alarmed as President Donald Trump considers following his controversial travel ban with restrictions on skilled foreign immigrants.

To crank out discoveries, U.S. biotech firms such as Amgen Inc. and Gilead Sciences Inc., as well as overseas companies with stateside operations, rely on the worlds best scientists and lower-level researchers with scarce expertise.

A crackdown on visas for these workers could set back research, including the treatment of cancer, executives said. It also comes as companies, hospitals and universities struggle with the aftermath of Trumps immigration ban from seven Muslim-majority countries, which has for now been blocked in court.

Theres a real crisis of science going on in this country, said Cedric Francois, chief executive officer of Apellis Pharmaceuticals, a startup based in Crestwood, Kentucky, that is working on immune-therapy drugs. About half of Apelliss staff come from abroad, largely brought in on the kind of visas, called H-1B, that allow temporary residence for skilled foreign workers.

Most, if not all of our people who are on a green card started off on an H-1B, said Francois, who is Belgian. Including me.

The Trump administration is considering changes to the scope of the H-1B program, one of the main routes through which U.S. employers sponsor skilled staff for immigration, White House spokesman Sean Spicer told reporters last week.

The administration may push to require companies to try to hire Americans first, and make it more difficult for lower-paid roles to qualify for the visas, in order to serve, first and foremost, the U.S. national interest, according to a draft executive order seen by Bloomberg. So far, no such changes have been announced, and the White House hasnt confirmed any details. Broader changes might require an act of Congress.

Politicians in both parties, as well as labor unions, have criticized the H-1B program because they say it lets companies undercut American wages. Some Democrats have also sought to restrict H-1B visas, including through a bill introduced by U.S. Representative Zoe Lofgren of California that would raise the minimum pay for such visa holders to $130,000.

Read More: Why H-1B Tech-Worker Visas Press Trumps Buttons

India-based outsourcing firms, such as Infosys Ltd. and Wipro Ltd., are among their largest users. Silicon Valley giants including Google Inc. and Facebook Inc. are also major H-1B sponsors, and have lobbied for years to make the category more flexible.

The Trump administration didnt respond to requests for comment. Trump has said its necessary to restrict travel from the seven countries because of the risk of terrorism.

U.S. bioscience firms employ about 1.7 million people, according to an industry-backed study, including a rising number of foreigners. Fewer than half of biomedical scientists in the U.S. in 2014 were native-born citizens, according to the journal Nature, and a third were non-citizens. Meanwhile, thousands of foreign scientists travel to the U.S. every year for specific projects.

The chief executives of two companies with U.S. operations, Roche Holding AG, Europes largest drug-maker, and Londons AstraZeneca Plc,assailed the restrictions.

Science doesnt have any borders, so anything that gets in the way of a borderless science exchange doesnt help, said Pascal Soriot,CEO of AstraZeneca, which has U.S. headquarters in Wilmington, Delaware, and research and manufacturing sites in Massachusetts and Maryland. We want to be able to move our people and our scientists around the world.

Trumps first executive order on immigration gave companies an early hint of what could become broader struggles. At Monrovia, California-based Xencor Inc., which works on drugs for immune diseases and cancer, one employee had to cancel a trip for fear of being stranded and another abandoned hope of a visit from an elderly relative overseas, according to CEO Bassil Dahiyat.

Xencor relies on its non-American staff, Dahiyat said: I can think of several off the top of my head who are absolutely pivotal.

Olivier Elemento, a computational biologist at Weill Cornell Medical College in New York, runs a cancer systems lab where two researchers have H-1B visas. The lab works on computational biology, where researchers analyze complex patient gene data to help find targets for new precision drugs -- an approach that has led to recent breakthroughs.

Our research would suffer without a doubt, Elemento said. A lot of discoveries we would make maybe wouldnt happen.

The immigration battle marks the second between drugmakers and the president. Last month, Trump accused the companies of getting away with murder by charging high prices for medicine and threatened to use the purchasing muscle of the federal government to drive costs down.

Exclusive insights on technology around the world.

Get Fully Charged, from Bloomberg Technology.

On Tuesday, more than 160 industry executives, scientists, and investors signed a letter to the journal Nature Biotechnology condemning Trumps earlier travel ban as a misguided threat to both liberty and innovation.

Medical leaders point to the central role of foreign doctors in the kinds of crises Americans fear. When the Boston Marathon bombings tore the city apart almost four years ago, a Greek doctor led Massachusetts Generals response: George Velmahos, chief of trauma surgery.

Mass General and its affiliated Brigham and Womens Hospital have 100 people with visas from the seven countries targeted by Trumps order, according to Katrina Armstrong, Massachusetts Generals physician-in-chief.

We brought them here because we thought they had the talent to make the country a better place, Armstrong said. These are people who couldnt be more dedicated to preventing violence and saving lives.

Read the rest here:

Trump's H-1B Visa Crackdown Threatens Cutting-Edge US Medicine - Bloomberg

WATCH: How abortion ushered in modern medicine – Salon

It seems like debates over vaccines are fairly recent phenomenon, but in truth, medical progress has always been fraught with controversy, competition, and ethical conundrums. In her new book The Vaccine Race: Science, Politics, and the Human Costs of Defeating Disease, author Meredith Wadman explores the story behind the creation of rubella vaccine a medical breakthrough that has helped generations of Americans have healthier childhoods. It also led to the development of numerous other important vaccines including ones for rabies, Hepatitis A and chicken pox.

Yet what many people may not know, Wadman explains, is that A good number of our modern day vaccines actually are made in two cells lines, both of them from legally aborted fetuses originating from Europe back in the early sixties. It was the development of these vaccines that established the fact you could use human cells as safe, clean mini vaccine factories a welcome alternative to previous, riskier work with animal cells. But it also created brand new questions about ownership of cells and what happens when human tissue is turned into profitable invention.

Today, nearly every person born in America since 1979 has been vaccinated against rubella with these cells roughly 140 million individuals. And Wadman says that that number is only a starting point. There are also all of the other people like all of our military recruits who additionally receive vaccines for different reasons. So if youre never worried about getting German measles, its because of a few cell lines, and a scientific race that played out nearly sixty years ago.

Go here to see the original:

WATCH: How abortion ushered in modern medicine - Salon

Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017* – Annals of Internal Medicine

In October 2016, the Advisory Committee on Immunization Practices (ACIP) voted to approve the Recommended Adult Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017. The 2017 adult immunization schedule summarizes ACIP recommendations in 2 figures, footnotes for the figures, and a table of contraindications and precautions for vaccines recommended for adults (Figure). These documents can also be found at http://www.cdc.gov/vaccines/schedules. The full ACIP recommendations for each vaccine can be found at http://www.cdc.gov/vaccines/hcp/acip-recs/index.html. The 2017 adult immunization schedule was also reviewed and approved by the American College of Physicians, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, and the American College of Nurse-Midwives. Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017.

Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017.

Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2017

Recommended immunization schedule for adults aged 19 years or older by medical condition and other indications, United States, 2017

Contraindications and precautions for vaccines recommended for adults aged 19 years or older*

Newly added to the 2017 adult immunization schedule is a cover page that contains information on select general principles pertinent to the adult immunization schedule, additional CDC resources, instructions for reporting adverse events related to vaccination and suspected cases of reportable vaccine-preventable diseases, and an ACIP-approved list of standardized acronyms for vaccines recommended for adults. In addition, the table of contraindications and precautions for vaccines routinely recommended for adults that was formerly a standalone document has been incorporated into the adult immunization schedule. Changes in the 2017 adult immunization schedule from the previous year's schedule include new or revised ACIP recommendations on influenza, human papillomavirus, hepatitis B, and meningococcal vaccinations.

LAIV should not be used during the 20162017 influenza season.

Adults with a history of egg allergy who have only hives after exposure to egg should receive age-appropriate inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV).

Adults with a history of egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress, lightheadedness, or recurrent emesis, or who required epinephrine or another emergency medical intervention) may receive age-appropriate IIV or RIV. The selected vaccine should be administered in an inpatient or outpatient medical setting and supervised by a health care provider who is able to recognize and manage severe allergic conditions.

Women through age 26 years and men through age 21 years who have not received any HPV should receive a 3-dose series of HPV at 0, 1-2, and 6 months. Men aged 22 through 26 years may be vaccinated with a 3-dose series of HPV at 0, 1-2, and 6 months.

Women through age 26 years and men through age 21 years (and men aged 22 through 26 years who may receive HPV) who initiated HPV series before age 15 years and received 2 doses at least 5 months apart are considered adequately vaccinated and do not need an additional dose of HPV.

Women through age 26 years and adult males through age 21 years (and men aged 22 through 26 years who may receive HPV) who initiated HPV series before age 15 years and received only 1 dose, or 2 doses less than 5 months apart, are not considered adequately vaccinated and should receive 1 additional dose of HPV.

Adults with chronic liver disease, including, but not limited to, hepatitis C virus infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, and an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level greater than twice the upper limit of normal, should receive a HepB series.

Adults with anatomical or functional asplenia or persistent complement component deficiencies should receive a 2-dose primary series of MenACWY at least 2 months apart and revaccinate every 5 years. They should also receive a series of MenB with either a 2-dose series of MenB-4C at least 1 month apart or a 3-dose series of MenB-FHbp at 0, 1-2, and 6 months.

Adults with HIV infection who have not been previously vaccinated should receive a 2-dose primary series of MenACWY at least 2 months apart and revaccinate every 5 years. Those who previously received 1 dose of MenACWY should receive a second dose at least 2 months after the first dose. Adults with HIV infection are not routinely recommended to receive MenB because meningococcal disease in this population is caused primarily by serogroups C, W, and Y.

Microbiologists who are routinely exposed to isolates of Neisseria meningitidis should receive 1 dose of MenACWY and revaccinate every 5 years if the risk for infection remains, and either a 2-dose series of MenB-4C at least 1 month apart or a 3-dose series of MenB-FHbp at 0, 1-2, and 6 months.

Adults at risk because of a meningococcal disease outbreak should receive 1 dose of MenACWY if the outbreak is attributable to serogroup A, C, W, or Y, or either a 2-dose series of MenB-4C at least 1 month apart or a 3-dose series of MenB-FHbp at 0, 1-2, and 6 months if the outbreak is attributable to serogroup B.

Young adults aged 16 through 23 years (preferred age range is 16 through 18 years) who are healthy and not at increased risk for serogroup B meningococcal disease may receive either a 2-dose series of MenB-4C at least 1 month apart or a 2-dose series of MenB-FHbp at 0 and 6 months for short-term protection against most strains of serogroup B meningococcal disease.

Significant changes in the 2017 adult immunization schedule footnotes include the following:

The format for the footnotes has been condensed, simplified, and standardized. The format for pneumococcal; human papillomavirus; meningococcal; varicella; and measles, mumps, and rubella vaccination footnotes have undergone significant revision.

Lastly, the table of contraindications and precautions for vaccines routinely recommended for adults, previously a standalone document, has been incorporated into the adult immunization schedule. The content of the table has been consolidated and simplified.

Work Group Chair: Laura E. Riley, MD, Cambridge, Massachusetts.

Work Group Members: John Epling, MD, MSEd, Syracuse, New York; Stephan Foster, Nashville, Tennessee; Sandra Fryhofer, MD, Atlanta, Georgia; Robert H. Hopkins Jr., MD, Little Rock, Arkansas; Paul Hunter, MD, Milwaukee, WI; Jane Kim, MD, Durham, North Carolina; Laura Pinkston Koenigs, MD, Springfield, Massachusetts; Maria Lanzi, ANP, MPH, Hamilton, New Jersey; Marie-Michele Leger, MPH, PA-C, Alexandria, Virginia; Susan M. Lett, MD, Boston, Massachusetts; Robert Palinkas, MD, Urbana, Illinois; Gregory Poland, MD, Rochester, Minnesota; Joni Reynolds, MPH, Denver, Colorado; Charles Rittle, DNP, MPH, RN, Pittsburgh, Pennsylvania; William Schaffner, MD, Nashville, Tennessee; Kenneth Schmader, MD, Durham, North Carolina; Angela Shen, PhD, Washington, DC; Rhoda Sperling, MD, New York, New York.

Work Group Contributors: Carolyn B. Bridges, MD, Atlanta, Georgia; Elizabeth Briere, MD, MPH, Atlanta, Georgia; Lisa Grohskopf, MD, MPH, Atlanta, Georgia; Rafael Harpaz, MD, MPH, Atlanta, Georgia; Charles LeBaron, MD, Atlanta, Georgia; Jennifer L. Liang, DVM, MPVM, Atlanta, Georgia; Jessica MacNeil, MPH, Atlanta, Georgia; Mona Marin, MD, Atlanta, Georgia; Lauri Markowitz, MD, Atlanta, Georgia; Noele Nelson, MD, PhD, Atlanta, Georgia; Tamara Pilishvili, MPH, Atlanta, Georgia; Mona Saraiya, MD, MPH, Atlanta, Georgia; Sarah Schillie, MD, Atlanta, Georgia; Raymond A. Strikas, MD, MPH, Atlanta, Georgia; Walter W. Williams, MD, MPH, Atlanta, Georgia.

Work Group Consultants: Tamera Coyne-Beasley, MD, MPH, Chapel Hill, North Carolina; Kathleen H. Harriman, PhD, MPH, RN, Richmond, California; Molly Howell, MPH, Bismarck, North Dakota; Linda Kinsinger, MD, MPH, Durham, North Carolina; Diane Peterson, St. Paul, Minnesota; Litjen Tan, PhD, Chicago, Illinois.

Work Group Secretariat: David K. Kim, MD, MA, Atlanta, Georgia.

Grohskopf

LA

Sokolow

LZ

Broder

KR

Olsen

SJ

Karron

RA

Jernigan

DB

et al

Prevention and control of seasonal influenza with vaccines.

MMWR Recomm Rep

2016

65

1

54

Meites

E

Kempe

A

Markowitz

LE

Use of a 2-dose schedule for human papillomavirus vaccinationupdated recommendations of the Advisory Committee on Immunization Practices.

MMWR Morb Mortal Wkly Rep

2016

65

1405

1408

Updated 2016 ACIP statement on October 2016 hepatitis B vaccination recommendations. MMWR. [Forthcoming]

MacNeil

JR

Rubin

LG

Patton

M

Ortega-Sanchez

IR

Martin

SW

Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016.

MMWR Morb Mortal Wkly Rep

2016

65

1189

1194

Updated ACIP statement on October 2016 meningococcal vaccination recommendations. MMWR. [Forthcoming]

Smith

JC

The structure, role, and procedures of the U.S. Advisory Committee on Immunization Practices (ACIP)

Vaccine

2010

28 Suppl 1

A68

75

National Vaccine Advisory Committee

Recommendations from the National Vaccine Advisory committee: standards for adult immunization practice.

Public Health Rep

2014

129

115

23

Williams

WW

Lu

PJ

O'Halloran

A

Kim

DK

Grohskopf

LA

See the rest here:

Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017* - Annals of Internal Medicine

Spine, sports medicine specialists to practice in DeKalb – DeKalb Daily Chronicle

Regional Medical Group orthopedic physicians Dr. Brian M. Babka and Dr. Jerome Kolavo will soon begin seeing patients in DeKalb. Both doctors will practice in the Medical Office Building at Northwestern Medicine Kishwaukee Hospital.

Babka is board certified in family medicine and sports medicine. He has clinical interests in sports medicine, overuse injuries, sports performance and sports concussion care. As a medical staff member of Northwestern Medicine Central DuPage Hospital since 2001 and a member of Northwestern Medicine Regional Medical Group, Babka has been instrumental in building a strong sports concussion and sports medicine program in the western suburbs. He serves on the faculty of Northwestern University Feinburg School Medicine, and he is team physician for DeKalb High School, Elgin High School, Waubonsee Community College and Kishwaukee College.

He has also served as a team physician for the United States Soccer Federation, and he has worked with United States Olympic Committee and several United States national teams. Babka completed medical school at Loyola University of Chicago Stritch School of Medicine, his residency and fellowship at Lutheran General Hospital.

Kolavo is board certified by the American Board of Orthopaedic Surgery. He has specialized interest in multiple spine surgeries including microsurgery of lumbar and cervical spine, reconstructive spinal surgery, spinal deformity surgery and minimally invasive spine surgery. Kolavo treats patients with both conservative and surgical solutions for degenerative conditions, chronic back and neck pain, injuries, and numbness in arms and legs. He treats all, from common conditions to complex surgeries to reduce pain, restore movement and improve quality of life.

Kolavo completed medical school at University of Illinois College of Medicine, his residency at Northwestern Memorial Hospital and his fellowship at Rush University Medical Center.

To learn about these physicians, visit kishhealth.org and nm.org. To make an appointment with Dr. Babka or Dr. Kolavo, call 815-748-5843.

Follow this link:

Spine, sports medicine specialists to practice in DeKalb - DeKalb Daily Chronicle

Greitens’ budget plan won’t fund MU Medical School | Miami Herald – Miami Herald


Washington Times
Greitens' budget plan won't fund MU Medical School | Miami Herald
Miami Herald
Gov. Eric Greitens' budget proposal for the state's 2018 fiscal year won't fund the new expansions for the University of Missouri Medical School in Columbia and ...
MU Medical School expansions won't get state funding next year under proposed budgetColumbia Missourian

all 102 news articles »

View original post here:

Greitens' budget plan won't fund MU Medical School | Miami Herald - Miami Herald

Med school hosts bariatric symposium – Sidney Daily News (subscription)

DAYTON The Wright State University Boonshoft School of Medicine and Premier Health will present a bariatric symposium, A Comprehensive Approach to Weight Loss, March 4, from 9 a.m. to 3 p.m., in the Bieser Auditorium of the Berry Building at Miami Valley Hospital in Dayton.

The bariatric symposium will explore the latest updates in nutritional guidelines, operative procedures and patient management for the bariatric surgery patient.

The symposium has been designed for physicians, surgeons, advanced practice nurses, registered nurses, psychologists, social workers, dietitians, allied health professionals who care for bariatric patients, medical fellows, medical residents and medical students.

Participants will learn about weight loss treatment options and the components of a comprehensive weight loss program, the spectrum of care for the bariatric patient and the roles of various health care providers in the care of the bariatric patient.

Guest speakers will be registered nurse Kellie Armstrong, manager of the Center for Bariatric Surgery at the Miriam Hospitals Center for Bariatric Surgery in Providence, Rhode Island; Dr. Dene Berman, clinical professor, WSU School of Professional Psychology, and adjunct professor, Department of Sociology, Anthropology, and Social Work, University of Dayton; Dr. Mukul Chandra, clinical associate professor, Department of Internal Medicine, WSU Boonshoft School of Medicine, cardiologist, Miami Valley Cardiologists Inc., and director, Preventive Cardiology and Clinical Research, Miami Valley Hospital; Theresa Gasper, bariatric patient; Kimberly Maloomian, lead dietitian, the Miriam Hospitals Center for Bariatric Surgery in Providence, Rhode Island; Dr. Joe Northrup, bariatric surgeon, Premier Health; Dr. Joon Shim, assistant professor, Department of Surgery, WSU Boonshoft School of Medicine, minimally invasive and bariatric surgeon, Wright State Physicians, director of the Heartburn Center, Miami Valley Hospital, and bariatric symposium chairman; Dr. Mujeeb Siddiqui, clinical assistant professor, Department of Surgery, WSU Boonshoft School of Medicine, and bariatric surgeon, Premier Health; and Mr. Siva Vithiananthan, associate professor of surgery (clinical), Brown University Alpert Medical School, site director for the surgical residency and medical student programs, the Miriam Hospital, Providence, Rhode Island, and chief of minimally invasive and bariatric surgery, the Miriam Hospital, Providence, Rhode Island.

Information about continuing medical education credits for this activity is available at medicine.wright.edu/bariatric-symposium.

To register for the symposium, go to medicine.wright.edu/bariatric-symposium. For information, call 937-208-2144 or email tmcory@premierhealth.com.

.

View original post here:

Med school hosts bariatric symposium - Sidney Daily News (subscription)

Welcome, Dell Medical School Travis County is counting on you – MyStatesman.com

Original publish date: July 10, 2016

Officials at the University of Texas were in a celebratory mood last week with the final opening days of the Dell Medical School, and rightfully so.

Its been a long road for UT 135 years, to be exact.

The struggle to bring a medical school to Austin makes the implications of this weeks opening crystal clear for this community: A single policy decision can change the course of history.

In 1881, the Texas Legislature via a voter referendum decided to build an academic institution in the states capital and a medical school in Galveston. That choice had the unforeseen effect of helping stabilize the Galveston economy once its position as a commercial center was wiped out by the hurricane of 1900. Investors fled and port commerce moved to Houston, but the medical school remained.

In Austin, that same decision left the capital city without the health and economic benefits that accrue to a city conducting medical research and training its own doctors. In 2016, Central Texans still travel to Galveston for state-of-the-art treatments that cannot be obtained anywhere else in the state.

With the first 50 students finishing their first week on the Forty Acres at Dell Medical School, it remains to be seen whether the political decisions that reversed that 135 years of history will pay off for the state of Texas and the residents of Travis County who voted to help foot the bill for the medical schools creation.

Austins aspirations for a comprehensive medical school have been in the works for decades. However, political will and economic realities never seemed to align political interest would always wane when the economy would inevitably sputter.

But in the late 2000s, Sen. Kirk Watson began pushing, first for more medical residencies and then later a full-throttle partnership between the university, Seton Healthcare Family and Central Health. In 2011, Watson laid out a complex but workable plan that would replace the aging city-owned hospital with one more suitable for full-scale medical education, modernize the existing clinic system and ensure the university of a continual flow of money to support the care of Travis County residents and develop the program.

At the time he said: Weve got to resist the temptation to keep waiting, watching and wishing. Weve got to throw out the past and reject the old excuses. We must not tell ourselves that somehow, sometime, some better deal will come along. It wont. This is the moment. This is our chance.

Rather than pursue full funding from the Legislature, Watson helped rally the call for a Travis County ballot initiative. If voters approved a tax increase, he argued, the region would add another economic driver and benefit from the research and clinical studies that stemmed from the work of the schools students and faculty.

WE SAID: Medical school in Austin a win-win proposition

So, in fall 2012, Travis County voters did their part, approving the measure, which added 5 cents to every property owners tax rate. And so, now begins the wait to see if that calculated risk will pay off.

The stakes are high. UT officials say the new medical school will develop a brand-new health care system to replace the current model that includes high costs, unpredictable outcomes and vast racial and economic disparities. On the surface, the face of this inaugural class is promising. According to Dell Medical School officials, 22 percent of the class identifies as an underrepresented minority (African-American, Hispanic or Native American), beating the national average of 13 percent. At the same time, the average MCAT score was in the 88th percentile; nationally the average is 83 percent, according to the American Medical Association.

That Dell Medical School has come this far is in no small part due to community goodwill goodwill toward the university, goodwill toward former Austin mayor and now senator Watson, goodwill toward the idea of a better medical future for rich and poor alike. Watson is absolutely correct that if this community had waited on the Legislature to fully fund the medical school, chances are high that Austin would still be waiting rather than welcoming its first class of future doctors.

But the gamble has come with critics as the city has continued to struggle with affordability and other governmental entities vie for property tax revenue to fund their own projects. Every group, whether it is Austin public schools, Austin Community College, Travis County or the city of Austin, has its own needs and a diminishing public appetite to pay for them with property taxes.

OTHERS SAID: Central Health needs a shot of accountability

Talking about the need of investment is easier than waiting for it to pay off. It will be four years before this class will graduate and start its residential training, which hopefully will lead to medical practices in Austin or in underserved Texas communities. It takes years, sometimes decades, to measure outcomes and develop a track record for success that builds a reputation like that at UT Medical Branch.

UTMB started with 23 students. Today it has more than 3,700. Austin had to start somewhere. We agree with Travis County Judge Sarah Eckhardt, who said, Were going to have to be really vigilant and honest about this partnership to assure the economic benefit works hand in glove with the improvement of health outcomes all the way down the economic ladder.

The 5 cents voters approved in 2012 is now actually 4.6 cents, according to Central Health officials. Last year, that amount raised $61.8 million, $35 million of which goes directly to the medical school. The rest is being used to leverage federal grants for health care programs in the county, according to Ted Burton, spokesman for Central Health.

Its important for all the partners UT, Central Health and Seton to keep the community up to date on their progress, while Travis County residents wait for our investment to start paying off. Its the only way to ensure there will continue to be goodwill for other important investments in the future.

See more here:

Welcome, Dell Medical School Travis County is counting on you - MyStatesman.com

Suppiger admitted to UW medical school – Bonner County Daily Bee

February 07, 2017 at 5:00 am |

(Courtesy photo) Madeline Suppiger of Sandpoint has been accepted into the medical school at the University of Washington in Seattle, Wash

Madeline Suppiger of Sandpoint has been accepted into the medical school at the University of Washington in Seattle, Wash. Suppiger will graduate from Washington University in St. Louis in May 2017 with a bachelors degree in world health and biology.

She attended Washington University, one of the most selective and rigorous universities in the country, on a full academic scholarship.

While at Washington University, Suppiger studied overseas in South Africa and Madagascar. She participated in medical research projects at Washington University Medical School and spent a summer semester studying organic chemistry at Harvard in Boston, Mass.

Suppiger is a lifelong resident of Bonner County and attended Lake Pend Oreille School District schools from kindergarten through twelfth grade.

A 2013 graduate of Sandpoint High School, she was valedictorian of her high school class. While in high school, Suppiger participated in Health Occupations, academic competition teams, and athletics.

She has earned numerous academic awards throughout high school and college including the deans list at Washington University, NASA Aerospace Scholar, and was picked by Gov. Butch Otter as one of two delegates from Idaho to the National Youth Science Camp in 2013. As a high school athlete, she made eight trips to state competition in track, volleyball, and soccer. Her SHS teams in soccer won a state championship in 2009 and finished as runner-up twice.

She is the daughter of Sally and Gary Suppiger of Cocolalla.

Notified of her acceptance promptly after her medical school interview in January 2017, she will represent Idaho in the WWAMI program at University of Washington School of Medicine.

The University of Washington School of Medicine is one of Americas top-ranked medical schools. Currently it is the only medical school serving the states of Washington, Idaho, Montana, Alaska and Wyoming. Suppiger is one of 230 students to be admitted from the five state region for the class of 2021. She will start medical school in August 2017.

After four years of medical school and additional years of residency training, Suppiger said she hopes to return to Idaho and practice clinical medicine in North Idaho.

Follow this link:

Suppiger admitted to UW medical school - Bonner County Daily Bee